Somatostatin receptors in pheochromocytoma

Frontiers of Hormone Research

Volumn 31, Issue , 2004, Pages 145-154

  De Herder, Wouter W ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 12344289836     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (43)

1. Solcia E, Kloppel G, Sobin LH: Histological Typing of Endocrine Tumours. Berlin, Springer, 2000.
2. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. N Engl J Med 1996;334:246-254.
3. Lamberts SW, Krenning EP, Reubi JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450-482.
4. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I- Tyr3]-octreotide: The Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716-731.
5. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439-1447.
6. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R: Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999;10:S23-S29.
7. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J: The clinical value of [90Y-DOTA]-Z)-Phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 2001;12:941-945.
8. Reichlin S: Somatostatin. N Engl J Med 1983;309:1495-1501.
9. Epelbaum J: Somatostatin in the central nervous system: Physiology and pathological modifications. Prog Neurobiol 1986;27:63-100.
10. Sevarino KA, Felix R, Banks CM, Low MJ, Montminy MR, Mandel G, Goodman RH: Cell-specific processing of preprosomatostatin in cultured neuroendocrine cells. J Biol Chem 1987;262:4987-4993.
11. Patel YC: Molecular pharmacology of Somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348-367.
12. Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB: Multiple gene transcripts of the Somatostatin receptor SSTR2: Tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 1993;192:288-294.
13. Vanetti M, Vogt G, Hollt V: The two isoforms of the mouse Somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization. FEBS Lett 1993;331:260-266.
14. Reisine T, Bell GI: Molecular biology of Somatostatin receptors. Endocr Rev 1995; 16:427-442.
15. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198.
16. Hofland LJ, Visser-Wisselaar HA, Lamberts SW: Somatostatin analogs: Clinical application in relation to human Somatostatin receptor subtypes. Biochem Pharmacol 1995;50:287-297.
17. Schally AV: Oncological applications of Somatostatin analogues. Cancer Res 1988;48:6977-6985.
18. Lamberts SW, de Herder WW, Hofland LJ: Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002;13:451-457.
19. Hoyer D, Lubbert H, Bruns C: Molecular pharmacology of Somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol 1994;350:441-453.
20. Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning E, Lamberts S: In vitro and in vivo detection of Somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 1992;74:1082-1089.
21. Epelbaum J, Bertherat J, Prevost G, Kordon C, Meyerhof W, Wulfsen I, Richter D, Plouin PF: Molecular and pharmacological characterization of Somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 1995;80:1837-1844.
22. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y: Identification of Somatostatin receptor subtypes and an implication for the efficacy of Somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93:1321-1325.
23. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M: Immunohistochemical expression of Somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 1999;5:3483-3487.
24. Hofland LJ, Liu Q, van Koetsveld PM, Zuijderwijk J, Van Der Ham F, de Krijger RR, Schonbrunn A, Lamberts SW: Immunohistochemical detection of Somatostatin receptor subtypes sstl and sst2A in human Somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999;84:775-780.
25. Reubi JC, Waser B, Liu Q, Laissue JA, Schonbrunn A: Subcellular distribution of Somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: Membranous versus intracellular location. J Clin Endocrinol Metab 2000;85:3882-3891.
26. Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, Baudin E, Luton JP, Plouin PF: Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf) 2002;57:629-634.
27. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB: Comparison of Somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902.
28. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ: [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-693.
29. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier C: Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 1995;36:1-6.
30. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hensen J, Lehnert H: Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 1997;46:39-44.
31. Cottin Y, Berriolo A, Guy F, Toubeau M, Belleville I, Brenot R, Brunotte F, Wolf JE: Somatostatin-receptor scintigraphy identifies a cardiac pheochromocytoma. Circulation 1999;100:2387-2388.
32. Kwekkeboom DJ, van Urk H, Pauw BK, Lamberts SW, Kooij PP, Hoogma RP, Krenning EP: Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993;34:873-878.
33. Invitti C, De Martin I, Bolla GB, Pecori Giraldi F, Maestri E, Leonetti G, Cavagnini F: Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. Horm Res 1993;40:156-160.
34. Koriyama N, Kakei M, Yaekura K, Okui H, Yamashita T, Nishimura H, Matsushita S, Tei C: Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: A case report with in vitro studies. Horm Res 2000;53:46-50.
35. Harrison M, James N, Broadley K, Bloom SR, Armour R, Wimalawansa S, Heath D, Waxman J: Somatostatin analogue treatment for malignant hypercalcaemia. BMJ 1990;300:1313-1314.
36. Plouin PF, Bertherat J, Chatellier G, Billaud E, Azizi M, Grouzmann E, Epelbaum J: Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: A placebo-controlled trial. Clin Endocrinol (Oxf) 1995;42:289-294.
37. Hofland LJ, Breeman WA, Krenning EP, de Jong M, Waaijers M, van Koetsveld PM, Macke HR, Lamberts SW: Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptorpositive cells in vitro and in vivo: Implications for somatostatin receptor-targeted radio-guided surgery. Proc Assoc Am Physicians 1999;111:63-69.
38. Smith MC, Liu J, Chen T, Schran H, Yeh CM, Jamar F, Valkema R, Bakker W, Kvols L, Krenning E, Pauwels S: OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion 2000;62:69-72.
39. Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, de Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP: Phase I study of peptide receptor radionuclide therapy with [In- DTPA]octreotide: The Rotterdam experience. Semin Nucl Med 2002;32:110-122.
40. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P: In- and Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-155.
41. Valkema R, Kvols L, Jamar F, Bakker WH, Smith C, Krennin EP, et al: Phase 1 study of therapy with 90Y-SMT 487 (OctreoTher) in patients with somatostatin receptor (SS-R) positive tumors. J Nucl Med 2002;43:33P.
42. Kwekkeboom DJ, Kam BL, Bakker WH, Kooij PP, de Herder WW, Srinivasan S, et al: Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors. J Nucl Med 2002;43:34P.
43. Jenkins SA, Kynaston HG, Davies ND, Baxter JN, Nott DM: Somatostatin analogs in oncology: A look to the future. Chemotherapy 2001;47:162-196.